2025-12-19 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the provided data:

**0. Executive Summary:**

JNJ is underperforming the S&P 500, with negative expected excess returns in the long term. Recent price action is mixed, with some positive momentum indicated by the 20-day moving average above the 60-day. However, the Market Risk Indicator suggests medium investment risk. Recent news is also mixed, covering both analyst downgrades and positive FDA news.

**1. Return Rate Comparison and Divergence:**

*   **JNJ Overview:** Johnson & Johnson is a global healthcare company focused on pharmaceuticals, medical devices, and consumer health products.
*   **JNJ Cumulative Return:** 60.54%
*   **S&P 500 (VOO) Cumulative Return:** 99.09%
*   **Divergence:** -38.5 (Current), Relative Divergence: 32.9
*   **Analysis:** JNJ has significantly underperformed the S&P 500 over the period considered. The negative divergence indicates JNJ's returns lagged significantly, while the relative divergence of 32.9 suggests it is near the bottom of its historical divergence range.
*   **Alpha, Beta Analysis:**
    | Year       | CAGR  | MDD   | Alpha  | Beta  | Cap(B) |
    |------------|-------|-------|--------|-------|--------|
    | 2015-2017  | 26.0% | 66.8% | -2.0%  | -0.1  | 336.6  |
    | 2016-2018  | 14.0% | 10.7% | -1.0%  | 0.1   | 310.9  |
    | 2017-2019  | 20.0% | 71.5% | -2.0%  | 0.4   | 351.4  |
    | 2018-2020  | 19.0% | 79.2% | -4.0%  | 0.4   | 379.2  |
    | 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5   | 412.2  |
    | 2020-2022  | 8.0%  | 79.6% | 9.0%   | 0.4   | 425.6  |
    | 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3   | 377.6  |
    | 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3   | 348.4  |
    | 2023-2025  | 32.0% | 79.6% | -32.0% | 0.1   | 501.9  |

    *   **CAGR:** The Compound Annual Growth Rate fluctuates significantly, highlighting inconsistent growth patterns.
    *   **MDD:** The Maximum Drawdown is consistently high, indicating significant potential losses during market downturns.
    *   **Alpha:**  Alpha is mostly negative, suggesting JNJ has historically underperformed relative to its risk level (Beta).  The positive Alpha in 2020-2022 is an exception.
    *   **Beta:** Beta values are generally low (around 0.3-0.5), indicating lower volatility than the market.
    *   **Cap(B):** Market capitalization has varied, reflecting company performance and market conditions.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 208.31
*   **Previous Close:** 210.33
*   **Change:** -0.96
*   **5-day SMA:** 210.738
*   **20-day SMA:** 206.296
*   **60-day SMA:** 195.3537

*   **Analysis:** The 5-day SMA is above the 20-day SMA which is also above the 60-day SMA, suggesting a potential short-term upward trend. The negative change from the previous close indicates a slight pullback.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 52.13 (Neutral)
*   **PPO:** -0.0426 (Slightly Bearish)
*   **Hybrid Signal:** Cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent (20 days) relative divergence change:** 10.2 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -48.4 (Negative long-term return)
*   **Analysis:**
    *   The MRI suggests a medium level of risk associated with investing in JNJ.
    *   The RSI is near neutral, indicating neither overbought nor oversold conditions.
    *   The PPO, slightly negative, could suggest a weakening trend.
    *   The Hybrid Signal recommends buying, suggesting a belief in the stock's potential but notes a low MRI value.
    *   The change in relative divergence indicates recent positive momentum.
    *   The expected return is highly negative, signaling potential underperformance compared to alternative investments.

**4. Recent News & Significant Events:**

*   **Mixed Sentiment:** The news headlines are a mixed bag.
    *   **Positive:** News regarding FDA approvals and analyst opinions justifying valuation premiums due to growth and mix premiumization.
    *   **Negative/Neutral:** Articles discussing share sales by institutions and exploration of valuation perspectives (potentially questioning current valuations), and price target & resistance level forecasting.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (2.16 on a scale of 1 to 5)
*   **Target Price:** $208.17 (Average), $240.00 (High), $155.00 (Low)
*   **Recent Rating Changes:** No specific changes provided.
*   **Analysis:** The consensus rating is positive, and the average target price is slightly below the current price. The wide range between the high and low target prices indicates significant disagreement among analysts. The lack of recent rating changes makes it difficult to gauge any shifts in sentiment.

**5. Recent Earnings Analysis:**

| 날짜         | EPS  | 매출      |
|-------------|------|----------|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3  | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2025-10-22 | 1.12 | 22.47 B$ |

*   **Analysis:** Revenue and EPS are relatively stable, with some fluctuations. The most recent quarter shows solid revenue, but the inconsistent EPS figures suggest potential margin pressures or one-time impacts. It is strange that 2024-10-23's data is provided twice.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|----------------|
| 2025-09-30   | $23.99B   | 69.56%         |
| 2025-06-30   | $23.74B   | 67.87%         |
| 2025-03-31   | $21.89B   | 66.40%         |
| 2024-12-31   | $22.52B   | 68.35%         |
| 2024-09-30   | $22.47B   | 69.01%         |

**Capital and Profitability:**

| Quarter      | Equity     | ROE   |
|--------------|------------|-------|
| 2025-09-30   | $79.28B   | 6.50% |
| 2025-06-30   | $78.47B   | 7.06% |
| 2025-03-31   | $78.11B   | 14.08% |
| 2024-12-31   | $71.49B   | 4.80% |
| 2024-09-30   | $70.16B   | 3.84% |

*   **Analysis:**
    *   Revenue shows a generally upward trend, with recent quarters showing strong performance.
    *   Profit margins are consistently high, indicating strong pricing power or efficient cost management.
    *   Equity is also increasing, suggesting healthy capital accumulation.
    *   ROE fluctuates, with a significant spike in the 2025-03-31 quarter.  This suggests potentially better use of equity in the first part of 2025 compared to the end of 2024.

**7. Comprehensive Analysis (Summary):**

JNJ's analysis presents a mixed picture. While revenue and profit margins are strong, the stock has underperformed the broader market. Technical indicators suggest a potential short-term upward trend, but the MRI indicates medium investment risk, and the expected long-term return is negative. Analyst opinions are generally positive, but target prices vary significantly. Recent news includes both positive developments (FDA news) and concerns about valuation and institutional selling. The inconsistent EPS and ROE figures warrant further investigation into the drivers behind these fluctuations.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.